Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
about
Lost in Translation (LiT): IUPHAR Review 6Role of coronary physiology in the contemporary management of coronary artery diseaseA comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and womenUse of statins and aspirin to reduce risks of cardiovascular diseaseDose of aspirin in the treatment and prevention of cardiovascular disease: current and future directionsCollaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' CollaborationDetermination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers.Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study.Antiplatelet therapy--Part IUse of antiplatelet agents in the management of thrombotic disorders.Atherosclerosis: inhibition of regression as therapeutic possibilitiesEtiology and pathophysiology of stroke as a complex trait.Review of HPLC methods and HPLC methods with mass spectrometric detection for direct determination of aspirin with its metabolite(s) in various biological matrices.Cranberry flavonoids, atherosclerosis and cardiovascular health.Tailored antiplatelet therapy and clinical adverse outcomes.Antiplatelet Aggregation and Antithrombosis Efficiency of Peptides in the Snake Venom of Deinagkistrodon acutus: Isolation, Identification, and Evaluation.Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application.Relationship between inflammatory markers and new cardiovascular events in patients with acute myocardial infarction who underwent primary angioplastyCardioembolic stroke. Primary and secondary prevention.Aspirin, platelet aggregation, and the circadian variation of acute thrombotic events.Aspirin use is associated with an improved long-term survival in an unselected population presenting with unstable angina.Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment.Prevention of cardiovascular disease: risks and benefits of aspirin.Antithrombotic therapy in end-stage renal disease.The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry).Roles of NSAIDs and aspirin in bleeding peptic ulcers : NSAIDs, aspirin and peptic ulcers.Observational evidence.Thrombosis and fibrinolysis in acute myocardial infarction.Antiplatelet therapy in the treatment of cerebrovascular disease.Long-term aspirin pretreatment in the prevention of cerulein-induced acute pancreatitis in ratsThe PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly)Aspirin may influence cellular energy status.Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy.Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use.Inhibitory effects of oligopeptides from hen egg white on both human platelet aggregation and blood coagulation.Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention.Effects of ezetimibe and anticoagulant combined therapy on progressing stroke: a randomized, placebo-controlled study.ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy.
P2860
Q24289150-5A894DC5-5F98-432D-90A4-402AD93498A2Q26827566-B41FE1DC-A9B6-44A1-A173-9AD09708467FQ28176072-76A05F9A-16D5-46AC-A6E7-CC7E2221F712Q28193248-6A15D868-9803-4C36-A88D-C2C288A68665Q28200895-E3DC3D48-395B-45C0-8641-EC3E368E1119Q29619529-DD8A5EA8-2860-44F4-9A46-9F9A7D576FE1Q33318499-1E4F41F9-6EFE-4A9D-B67F-A5AC7FCB32DEQ33428688-A02484A0-0ED0-4B00-8C19-883D15F667C9Q33606832-676104B3-380A-4BE6-B1C1-9C1DA7F8DEBEQ33606862-8A7910DE-3A3C-4B75-96BB-66A57499C2B6Q33611394-F0976777-6FBB-40E5-A711-F9D8B2F23A4AQ34065857-A44048E4-DFE0-4156-B358-168BA85C1A1AQ34148636-2FCF69F1-328F-4869-B10B-6192B6725F54Q34680471-C6F1261E-C860-4738-A183-3B2DF826923DQ35032042-98CA453B-9965-43C6-8129-6871B79A58FBQ36119618-6150C24D-58B1-4391-94B4-74DD51623B3EQ36482113-D6B9F348-74E9-4EB4-952D-CE09262C2821Q36647655-CDC525D2-B0BB-4CC5-8DF8-3E528A62C9DBQ36819594-BBA581D2-4218-4DC0-9FFF-62DB93FADAC7Q37054778-9EF67CC2-B11B-4CD7-A3FF-3BB078F9446CQ37202179-EC61B8D5-6CD6-46FD-901E-328CDDD369F9Q37407452-0570DA24-A68F-4859-958E-7EEFFD92E31CQ37981860-3F962C22-3C1C-41E6-9452-16955850F598Q39329927-421C5CBF-EE7D-4500-9B7E-01B51FB20C3AQ39863322-273E6A0B-54A8-4E4A-80CA-408A1946E8D3Q40086146-74F040DE-56C5-4702-84E9-A8189C0229A6Q40756651-1F186648-84F1-44AB-9DFF-3E1AD48E2AC8Q40759551-6F1A80FE-82CB-408B-BD67-839EC7710792Q40772706-EB8C5382-31E9-4950-844D-DCCC01BC6EA0Q40918222-6C5A3167-9C8C-4E72-B3E8-AB043C2DBA53Q41030698-DE0A8733-B65E-48A9-BB66-3DA7901AFFF1Q41905465-C9BEBD54-D288-4119-811C-F7C2C3906777Q42167071-D40DE035-50EA-427A-BB97-B6E6893100BEQ43201529-878E851A-8DAA-49BA-AA3B-87E052E457B4Q45331959-C3144F5B-19BF-4E26-A18F-4EECEE9C384CQ45951805-4738ADF1-1904-4F64-9E65-9EB9C1B65EE7Q46755092-1B9A6263-2CB0-47B6-B30E-53D01727383BQ49045325-5CEFE13D-FAE1-4C3B-8111-3CCEEC2CA752Q51059883-877A6311-EFE6-489F-9E73-C8ED4AB788FF
P2860
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Aspirin and other antiplatelet ...... ion of cardiovascular disease.
@en
type
label
Aspirin and other antiplatelet ...... ion of cardiovascular disease.
@en
prefLabel
Aspirin and other antiplatelet ...... ion of cardiovascular disease.
@en
P2093
P356
P1433
P1476
Aspirin and other antiplatelet ...... ion of cardiovascular disease.
@en
P2093
P304
P356
10.1161/01.CIR.80.4.749
P407
P577
1989-10-01T00:00:00Z